Health-Related Quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-Based Treatment, with and without Interferon: a prospective observational study in Egypt by Youssef, Naglaa F A et al.
RESEARCH ARTICLE Open Access
Health-related quality of Life in patients
with chronic hepatitis C receiving
Sofosbuvir-based treatment, with and
without Interferon: a prospective
observational study in Egypt
Naglaa F. A. Youssef1, Mohamed El Kassas2, Amany Farag1 and Ashley Shepherd3*
Abstract
Background: The Egyptian government introduced the first directly acting antivirals (DAAs) into Egypt through the
government funded National Treatment Program. As yet, there has been no investigation into the effects of these
new DAAs therapies on patient reported outcomes (PROs). This study aimed to (1) assess the PROs (health-related
quality of life (HRQoL), mental health and perceived social support) of HCV patients receiving DAAs therapy prior,
during and at the end of therapy; (2) evaluate PROs of Interferon-free (dual) users versus Interferon-containing
(triple) users cross the three different time periods; and (3) identify the predictors of HRQoL of DAAs therapy users
cross the three different time periods.
Methods: A prospective observational design was used. Patients with chronic HCV undergoing treatment following
the Egyptian National Guidelines at one of the national treatment centers were approached. Data collection
occurred in the period from February to October 2015. Data was collected at three time points: (1) baseline (time 0:
T0), before initiating therapy); (2) 5/6 weeks after initiation of therapy (time 1 of therapy: T1) and at the end of the
therapy (Time 2: T2). Four PROs questionnaires were utilized for data collection: (1) Multidimensional Scale of
Perceived Social Support (MSPSS), (2) The Depression Anxiety Stress Scales (DASS-21), (3) the Liver Disease
Symptom Index-2.0 (LDSI-2.0) for testing disease specific HRQoL and (4) the Center for Adherence Support
Evaluation (CASE) Index, alongside the background data sheet.
Results: Sixty-two patients participated. There was a change in HRQoL, symptom experience and mental health
across the three different time periods. HRQoL was impaired more after starting the course of therapy (T1) than at
baseline (T0) and end of therapy (T2), z≥ -2.04, p ≤ .04. Also, symptom experience deteriorated more during the
treatment period than at the baseline, Z ≥ -1.97, p ≤ .04. Anxiety and stress were significantly higher during the
treatment period than at the end of treatment. Perceived social support was significantly higher during the
treatment period than at baseline and end of therapy, Z ≥ -2.27, p ≤ .023. During the course of therapy, triple users
were more likely to report poorer HRQoL and anxiety than dual users (p ≤ .04). By the end of therapy, the two arms
of therapy had no significant differences in any of the PROs.
At baseline, the predictor model significantly (p = .000) explained 37.5% of the variation in the HRQoL prior to
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therapy. Depression was the main variable that contributed to (41.3%) predicting change in HRQoL prior to therapy.
During therapy, the model significantly (p = .000) explained 76% of the variation in the HRQoL-T1. Stress-T1, body
mass index (BMI)-T1 and HRQoL-T0 significantly and respectively predicted 44.4, 46.5 and 31.1% of the variation in
HRQoL-T1. At the end of therapy, the model significantly (p = .000) predicted 80.5% of the variation in the HRQoL-
T2. HRQoL-T1 and anxiety-T2 significantly predicted 72.3 and 61.6% of the variation in HRQoL-T2.
Conclusions: Baseline HRQoL, depression and BMI should be systematically assessed before starting the antiviral
therapy for early detection and the improvement of the impairment before the initiation of therapy. Anxiety should
be frequently assessed and followed up through the course of antiviral therapy. The triple group required more
nursing and practitioner attention due to increased anxiety levels and impaired HRQoL during the treatment therapy.
Keywords: Directly acting antivirals-DAAs, Health related quality of life, Social support, Patient reported outcomes
(PROs), Hepatitis C Virus antiviral therapy
Background
Worldwide, the prevalence of the hepatitis C virus
(HCV) is 2.8%, causing a considerable global burden
of morbidity and mortality [1, 2]. According to a na-
tionally representative survey carried out in 2008 [3],
Egypt has the highest HCV prevalence in the world; with
14.7% sero prevalence. Hepatitis C has been associated
with substantial resource utilization as a result of its effect
on the liver as well as other organ systems (the extrahe-
patic manifestations of HCV) [4, 5]. It has been widely
reported to have a profound negative impact on pa-
tient’s health-related quality of life (HRQoL) because
of the associated complications of advanced liver dis-
ease (i.e. encephalopathy, variceal hemorrhage, ascites)
[6]. Also, employees being treated for hepatitis C had
high rates of absenteeism and impairment of their
work productivity [7]. HCV affects HRQoL through
other avenues, such as fatigue, persistent flu-like
symptoms, joint pain, itching, sleep disturbances, ap-
petite changes, nausea, and depression [8, 9].
Patient reported outcomes (PROs) have become in-
creasingly important data in clinical research, since
they can provide the most complete assessment of
the impact of chronic hepatitis C and its treatment
on patients’ health status [10]. PROs have been de-
fined as measurements that are based on reports
that come directly from the patients about their
health status without any amendment or interpret-
ation by healthcare providers [11]. There are a num-
ber of important PROs that provide insight into
patients’ experiences such as HRQoL. HRQoL has
been defined as the patients’ subjective perception of
the impact of their disease and/or its treatment on
their daily life, and their physical, psychological and
social functioning. These definitions clearly acknow-
ledge that HRQoL is a multidimensional concept.
Therefore, it has been considered the gold standard
to measure patients’ experiences with their disease
and treatment [12].
A number of antiviral therapies have been developed.
Antiviral therapies can eradicate the virus resulting in
improvements in liver histology, which prevents liver-
related mortality [13] and enhances HRQoL because of
symptoms’ alleviation and an increase in associated eco-
nomic and social benefits. For example, work force par-
ticipation and removal of social stigma can follow after
successful treatment [13–15]. However, the toxicity asso-
ciated with antiviral treatments can negatively affect
HRQoL by way of diminished physical, emotional and
social functioning [7, 16].
A pegylated interferon (peg-IFN)-based regimen has
long been the standard treatment for patients with HCV
[17]. Treatment with a peg-IFN-containing regimen has
been shown to severely impair all PROs including work
productivity, leading to negative patient experiences and
lower adherence to the treatment regimen [7, 16].
The arrival of direct acting antivirals (DAAs), such as
bocepreveir and telaprevir, in triple combination with
peg-IFN and ribavirin, increased HCV clearance rates
but might cause adverse effects that can further decrease
HRQoL [18, 19]. Over the past few years, the treatment
landscape for HCV has been changing rapidly, leading to
the introduction of newer and improved, DAAs. Even in
patients who were considered difficult to treat; these
agents have reduced toxicity, increased barriers to resist-
ance and led to reduced side effects [20–23] such as fa-
tigue and neuropsychiatric problems [24]. The
interferon-free treatment (dual) can potentially provide a
number of important advantages; including higher effi-
cacy, lower side effects and shorter duration of treat-
ment, which can substantially increase adherence level
and improve PROs [25].
The Egyptian government introduced sofosbuvir as the
first DAAs into Egypt through the government funded
National Treatment Program [26]. The first DAAs regi-
men used in the country was sofosbuvir, which was ad-
ministered either as a triple therapy in combination with
peg-IFN and ribavirin or as a dual therapy combined
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only with ribavirin (for interferon non-eligible patients).
As of July 2015, other treatment options, including an
all DAAs therapy with simepravir and sofosbuvir were
introduced, with many more DAAs containing therapies
soon to be approved [26].
To date, there have been no investigations into how
Egyptian HCV patients receiving the new DAAs perceive
their HRQoL. Therefore, this study is the first to evalu-
ate a number of PROs, including health-related quality
of life (HRQoL), mental health status (i.e. depression,
anxiety and stress), and perceived social support among
HCV patients, while receiving DAAs therapy; either an
interferon-free or interferon-containing regimen.
Specifically this study aimed to:
1) Assess the PROs (i.e. health-related quality of life,
mental health and perceived social support) of HCV
patients receiving direct acting antivirals (DAAs)
therapy prior, during and at the end of therapy.
2) Evaluate PROs of Interferon-free (dual) users versus
Interferon-containing (triple) users prior, during and
at the end of treatment.
3) Identify the predictors of HRQoL of DAAs therapy
users prior, during and at the end of therapy.
Methods
Study design
A prospective observational design was used to conduct
this study. Patients with chronic HCV being treated,
using the Egyptian National Guidelines at one of the na-
tional treatment centres, were approached to participate.
According to the most updated treatment protocol, pa-
tients undergo therapy for a relatively short period (3 to
6 months).
Study population
A total of 80 patients were invited to participate in the
study in the period from February to October 2015. Pa-
tients were randomly selected from HCV patients visit-
ing the HCV specialized clinic. Patients were eligible to
participate in the study if they met the following criteria:
 Had no significant psychiatric illnesses (diagnosed
by psychiatrist),
 Aged 18 years or older,
 Eligible for starting DAAs therapy and
 Gave written consent to participate.
Data collection
This study was conducted at the Outpatients clinic of
the National Hepatology and Tropical Medicine Re-
search Institute (NHTMRI), Cairo, Egypt. This institute
is one of 42 specialized national treatment centres for
treatment of viral hepatitis distributed throughout the
country; and it is the largest of all these centres. This in-
stitute serves patients from different regions in Egypt
and of various socioeconomic status. All the centres fol-
low the same set of national guidelines for the treatment
of patients with chronic HCV and are supervised by the
National Committee for Control of Viral Hepatitis.
Data was collected at three points in time: (1) baseline
[time 0 (T0), before initiating therapy]; (2) 5th or 6th
week after initiation of therapy [time 1 (T1) of therapy]
and (3) at the final week of therapy [time 2 (T2)]. At
time 0, the patients were first interviewed following an
appointment with the consultant in the outpatients’
clinic, where it was confirmed that they were eligible to
start the HCV therapy.
Protocol of therapy
According to the 2014 Egyptian HCV national patient
treatment guidelines, antiviral therapy was administered
either as Interferon-free (dual) or Interferon-containing
(triple) therapies. The recommended regimen for pa-
tients who were not eligible to receive peg-IFN (dual
group) was daily Sofosbuvir (400 mg) plus weight-based
RBV (1000 mg [<75 kg] to 1200 mg [>75 kg]) for
24 weeks. Inclusion criteria for treatment of patients
who would be treated with Interferon free regimen was
defined with the presence of any or all the following;
a) Child score up to 8
b) Total bilirubin ≤ 5
c) Albumin ≥ 2.5
d) Platelet count ≥ 30,000
e) Prtothrombin concentration ≥ 50%
f) Hemoglobin concentration ≥ 10 mg
Patients who were eligible to receive Interferon (triple
group) would be treated with daily Sofosbuvir (400 mg)
and weight-based RBV (1000 mg [<75 kg] to 1200 mg
[>75 kg]) plus weekly Peg-INF for 12 weeks.
Collection data procedure
Questionnaires and data collection
Four instruments were utilized for data collection along-
side the background data sheet. Participants were inter-
viewed face to face for around 30–40 min each, based
on the patient co-operation and literacy level, to
complete all the questionnaires.
The Multidimensional Scale of Perceived Social Sup-
port (MSPSS) [27] is a commonly used instrument for
measuring the perceived adequacy of social support
from three specific sources: family, friends and signifi-
cant others [26]. Each subscale has four items that are
rated on a seven point scale in the English version or on
a three point scale in the Arabic version. The MSPSS
can be computed to give the total and subscale scores
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for each of the three sources of support. The total score
and subscale scores are calculated by adding up the par-
ticipant’s responses. An increasing score represents in-
creasing perceived adequacy of social support. This is
the most appropriate tool for measuring perceived social
support among patients waiting for OHS for many rea-
sons. (1) It is the shortest and simplest tool available (12
items); (2) An Arabic version of MSPSS is available [27]
and has been widely used among Arabic speaking people
[26]. It has a high construct validity and internal
consistency reliability with Cronbach’s alpha for total
MSPSS = 0.74 [27].
The Depression Anxiety Stress Scale (DASS-21) [28]
was used to assess mental health. The DASS-21 ques-
tionnaire includes 21 questions that measure anxiety,
stress and depression separately, where each scale has
seven questions. Each question is scored on a 4-point
combined severity/frequency scale over the past week.
The score ranges from 0 (did not apply to me at all) to 3
(applied to me very much, or most of the time). The
overall score ranges from 0 to 21. Scores 0–4, 0–3 and
0–7 show normal levels of depression, anxiety and stress
respectively; scores 5–7, 4–5 and 8–9 show low levels of
depression, anxiety and stress respectively; scores of 8–
11, 5–7 and 10–13 show moderate levels of depression,
anxiety and stress respectively; scores 12–15, 8–9 and
14–17 show severe levels of depression, anxiety and
stress respectively; and scores of 25+, 10+ and 18+ show
extreme severe levels of depression, anxiety and stress
respectively. Scores for depression, anxiety and stress are
calculated by adding the scores for the relevant items.
The Arabic version of this tool has been psychometric-
ally validated.
The Liver Disease Symptom Index (LDSI)-2.0 is a
short and psychometrically tested disease specific
HRQoL questionnaire, which has been widely used with
patients at different stages of a chronic infection with
HCV [29, 30]. It is available in Arabic [29]. The LDSI-
2.0 has two subscales that are used to assess symptom
severity, and the impact of these symptoms on patients’
daily activities (symptom hindrance). The participants
were asked if a symptom was experienced during the
past week. If yes, the participants were asked to what ex-
tent it was affecting their daily lives and social contacts
on a five-point Likert scale, with 0 = not at all, and 4 = to
a high extent. Possible scores for each subscale ranged
from 0 to 60 for the severity dimension and 0–36 for
hindrance dimension. A higher score on the severity di-
mension represents a higher perception of the symp-
toms’ severity, and a higher score on the hindrance
dimension represents a higher perception of the limita-
tions of daily activities because of these symptoms. It
also provides an overall total score that represents a dis-
ease specific HRQoL [29, 30].
The Center for Adherence Support Evaluation (CASE)
Index [31] is a valid, reliable, simple and easy to admin-
ister instrument that measures self-reported antiretro-
viral therapy adherence. It is composed of three
questions: Question 1: Self-reported frequency of ‘diffi-
culty taking HCV medications on time’, with responses
being: never, rarely, most of the time or all of the time.
Question 2: Self-reported ‘average number of days per
week at least one dose of HCV medications was missed’,
with responses being: every day, 4–6 days per week, 2–3
days per week, once a week, less than once a week or
never. Question 3: Self-reported ‘last time missed at least
one dose of HCV medications’, with responses being:
within the past week, 1–2 weeks ago, 3–4 weeks ago, be-
tween 1 and 3 months ago, more than 3 months ago or
never. The total index score (INDEXSCORE) > 10 indi-
cates good adherence, while < 10 indicates poor
adherence.
Socio-demographic and medical data sheets were de-
signed by the researchers and divided into two parts: (i)
the socio-demographic sheet was used to collect data re-
lated to the participants’ characteristics; such as age,
gender, employment status, occupation, education level,
marital status and medical history, and (ii) the medical
data sheet was used to record the diagnosis, disease dur-
ation, type of antiviral therapy, comorbidity (i.e. diabetes,
hypertension), and other factors. The Body Mass Index
(BMI) was calculated using the standard formula: BMI =
kg/m2.
Statistical methods
The Statistical Package for the Social Sciences 20 (IBM
SPSS, Armonk, New York, United States) was used for
the data analysis. Descriptive statistics were computed to
summarize data. Individual variables were examined by
percentages, means, and SDs. A non-parametric statis-
tical technique, such as chi-square for independence,
was used to compare the frequencies of nominal vari-
ables. Differences among the two arms of therapy were
examined by independent t test. Friedman test was used
to examine the change in HRQoL, mental health and so-
cial support at the three time points. Wilcoxon Signed
Rank Test (Post-hoc pairwise) with Bonferroni correc-
tion was performed for HRQoL, mental health and so-
cial support across the three time points. A multiple
linear regression analysis using “stepwise forward
method” was used to investigate the factors associated
with HRQoL. Since this was an exploratory study, there
was no prior decision regarding the order of entering
the variables in the model [32]. The multiple regression
assumptions were investigated and there was no viola-
tion of normality, linearity, and multicollinearity. All
statistical analyses were two tailed with p < .05 as the sig-
nificance level.
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Results
Characteristics of the participants
Sixty-two patients in total participated in this study at
T0 and T1; and 36 participated at T2 (Fig. 1). The base-
line demographic and medical characteristics revealed
that the mean age of the sample (n = 62) was 54.06
± [standard deviation (SD) 10.41 years] (Table 1). The
sample contained an almost equal number of males
(48.4%) and females (51.6%). Most of the sample were
married (72.6%), and employed (64.3%). There was an
equal distribution between cirrhotic and non-cirrhotic
participants, with disease discovery duration ranging
from 3 to 216 months. Half of the participants had a
medical comorbidity, with diabetes (30.6%) and hyper-
tension (24.2%) the most commonly reported comorbidi-
ties (Table 1). About 87.1% of the patients were
treatment naïve which meant they had never received
HCV antiviral therapy before this study. Experienced pa-
tients had previously received HCV antiviral therapy
(peg-IFN).
Comparison between males and females
A comparison between males (n = 30) and females (n =
32) demographic and medical data at baseline and their
PROs through the three time points was conducted.
Only significant results are presented in Table 2. As has
been observed, females were more likely to be older and
obese than males. Prior to therapy, females had a poorer
HRQoL, higher levels of symptoms’ severity, hindrance
of symptoms in their daily life, and a higher level of
depression, than males. During the course of therapy,
depression remained higher among females than males.
At the end of therapy, there was no significant difference
between males’ and females’ PROs.
Objective 1: PROs (health-related quality of life, mental
health and perceived social support) of HCV patients
receiving DAAs therapy prior, during and at the end of
therapy
Friedman test for repeated measures was computed,
among the patients who participated at the three differ-
ent time points (n = 36), to compare HRQoL [LDSI-2.0
total score], symptom experience [two subscales of
LDSI-2.0: severity and hindrance], mental health [de-
pression, anxiety and stress], and perceived social sup-
port across the three different time points (Table 3).
There was a significant effect for time on HRQoL, X2
= 8.35, p = .015. A Wilcoxon Signed Rank Test with Bon-
ferroni correction was performed between each of the
time points with r indicating the effect size based on the
Cohen criteria. A Wilcoxon Signed Rank Test revealed
there was a statistically significant impairment of
HRQoL after starting the course of therapy (T1) than at
baseline (T0) and end of therapy (T2), z ≥ -2.04, p ≤ .04,
with a medium effect size (r ≥ -.26) (Table 3).
Also, there was a significant effect for time (T0 vs. T1)
on symptom experience (severity & hindrance) and
mental health (depression & anxiety), (X2 = 5.41, 9.89,
8.79, 6.82 respectively, p < .05). A Wilcoxon Signed Rank
Test revealed there was a statistically significant impair-
ment of symptom experience and mental health during
the treatment period (T1, 5/6 weeks) than at the
baseline, Z ≥ -1.97, p ≤ .04, with a medium effect size
(r ≥ -.25). Additionally, anxiety and stress were signifi-
cantly higher during the treatment period than at the
end of treatment. Perceived social support was also sig-
nificantly higher during the treatment period than at
baseline (T0) and end of therapy (T2), Z ≥ -2.27,
p ≤ .023, with a medium effect size (r ≥ -.29) (Table 3).
Comparison of basic demographic and medical data
between dual and triple users
For the purpose of comparing dual and triple therapy
users, the baseline demographic and medical characteris-
tics of the two groups of participants were initially
compared using the nonparametric statistical tests (i.e.
Chi-square test and independent-samples Mann-
Whitney U Test). Dual participants were more likely to
live in urban areas (Pearson Chi-Square = 7.123, p = .02)
and more cirrhotic (Pearson Chi-Square = 7.806, p = .01)
than triple therapy participants. However, the rates of
baseline factors that could potentially impact HRQoL-T1
(i.e. age, gender, employment status, depression-T0,
anxiety-T0, stress-T0, disease duration, PCR-T0, BMI-
Fig. 1 Sample flow diagram
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T0, symptom severity-T0, symptom hindrance-T1 and
HRQoL-T0) were similar between the two arms of ther-
apy (all P ≥ .05) (Table 4).
Comparison of HRQoL, mental health and symptom
experience between dual and triple users
Table 4 presents the comparison of PROs (i.e. HRQoL,
mental health and symptom experience) between the
dual and triple therapy users at the three points in time.
During the course of therapy (after 5/6 weeks), triple
users (n = 31) were more likely to report poorer HRQoL
and anxiety than dual users (n = 31) (p ≤ .04). Using
Pearson correlation showed that there is a high signifi-
cant association between anxiety and HRQoL during the
treatment period (r - = .78, p = .000). Anxiety during the
time period was significantly correlated with baseline
HRQoL (r = .51. p = .000). By the end of therapy, the two
arms of therapy had no significant differences in any of
the PROs (Table 5). A post hoc power calculation for
the Mann Whitney U test of differences in HRQoL be-
tween the dual and triple therapy group during treat-
ment is estimated power of 0.33.
Objective 2: PROs of dual users versus triple users prior,
during and at the end of treatment
The pattern of change in PROs among triple (n = 26)
and dual (n = 10) therapy users prior, during and at the
end of therapy was considered using Friedman test
(Table 6). Results revealed that the triple therapy group
had significantly poorer HRQoL, symptom severity,
symptom hindrance and depression, and more increase
in perceived social support score at T1 than at baseline,
(Chi-Square ≥ 6.653, p ≤ .036). In contrast, dual users
had no significant change in their HRQoL, symptom ex-
perience and mental health (Chi-Square ≤ 5.706,
p ≥ .058), while their perceived social support was signifi-
cantly increased during T1 in comparing to T0 and T2
(p = .037) like triple users (Table 6). A post hoc power
calculation for the Friedman test of change in HRQoL in
the dual group over time is estimated power between
0.21 and 0.41.
Table 1 Baseline demographic and clinical characteristics of the
participants
Number
(total 62)
Percent
Age 54.06 ± 10.41*
Gender
• Males 30 48.40
• Females 32 51.60
Education
• Uneducated 24 38.70
• Can read and write or preparatory 12 29.00
• Secondary 12 19.40
• University 8 12.90
Marital status
• Unmarried 17 27.40
• Married 45 72.60
Employment status
• Unemployed 17 27.40
• Employed 17 27.40
• Housewife 28 45.20
Residence area
• Rural 15 24.20
• Urban 47 75.80
Diseases stage
• Non cirrhotic 31 50
• Cirrhotic 31 50
Number of comorbidities
• 0 31 50
• 1 17 27.4
• 2 11 17.7
• 3 3 4.8
Type of comorbidity
• Hypertension 15 24.20
• Diabetes 19 30.60
• Others (renal disease, disc, heart disease,
asthma, peptic ulcer)
11 17.70
Disease duration (Range from 3 to 216 months) 71.10 ± 57.72*
Type of treatment
• Dual 31 50
• Triple 31 50
Treatment experience
• Naive 54 87.10
• Experienced 8 12.90
Treatment paying method
• Self 6 9.70
• Governmental 56 90.30
Table 1 Baseline demographic and clinical characteristics of the
participants (Continued)
BMI
T0 30.6 ± 4.24*
T1 30.4 ± 4.53*
PCR at T1 (50 cases)
• Negative 32 64
• Positive 18 36
BMI body mass index, PCR Polymerase Chain Reaction, T0 Time 0, T1 time 1
*Mean ± SD
*P value: * ≤ .05 at two tailed
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Objective 3: Predictors of HRQoL of DAAs therapy users
prior, during and at the end of therapy
At baseline, the developed model could significantly (P
= .000) predict 37.5% (R2 = 39.8, AdjR2 = 37.5) the vari-
ance in the HRQoL prior to therapy. Depression and
anxiety were significant variables that contributed to
predict the change in HRQoL prior to therapy (41.3 &
29.1% respectively) (Table 7). All the other variables
were excluded from the model as they could not signifi-
cantly predict the HRQoL-T1: age, gender, PCR-T0,
BMI-T0, MSPSS-T0 and stressT0.
After 5/6 weeks of therapy (T1), the model signifi-
cantly (P = .000) explained 76% (R2 = 78.2, AdjR2 = 76)
the variance in the HRQoL. Out of 15 independent fac-
tors that entered the model, only HRQoLT0 & BMIT0
prior to therapy; and StressT1, Anxiety-T1 & BMI-T1
during therapy significantly explained the variation in
HRQoL during the course of therapy. The five variables
could significantly and prospectively predict 31.1, 35,
44.4, 24.4 & 46.5% of the variations in HRQoL during
therapy (Table 7). All the other variables could not sig-
nificantly predict the HRQoL during therapy: age, gen-
der, PCR-T0, MSPSS-T0, MSPS-T1, depression-T0,
anxiety-T0, stress-T0 and depressionT1, NDEXSCORE-
T1, type of therapy.
At the end of therapy (T2), the model significantly (P
= .000) predicted 80.5% (R2 = 83, AdjR2 = 80.5) of the vari-
ance in the HRQoL-T2. Out of 22 independent variables,
four variables (HRQoL-T1, Anxiety-T1, Anxiety-T2,
MSPSS-T2,) could significantly predict the variation in
HRQoL. HRQoL & anxiety during the course of therapy
and perceived support & anxiety at the end of therapy sig-
nificantly and respectively predict 72.3, 33.1, 25.3 & 61.6%
of the variations in HRQoL-T2 at the end of therapy
(Table 7). All the other variables could not significantly
predict the HRQoL-T2: depression-T2, stress-T2, HRQoL-
T0, MSPSS-T0, MSPSS-T1, depression-T0, anxiety-T0,
stress-T0, depression-T1, stress-T1, INDEXSCORE-T1,
T1INDEXSCORE-T2, age, gender, disease duration, PCR-
T1, BM-IT0 and MBI-T1.
The key finding of this study is that anxiety was always
the constant variable that could significantly predict
change in HRQoL during the three different time
periods.
Discussion
Healthcare consumers, whether patients or policy makers,
are increasingly interested in how medical intervention
impacts PROs, such as patient’s HRQoL [33–36]. There-
fore, several studies examined the HRQoL among HCV
on antiviral therapy; and agreed that Peg-IFN and ribavirin
therapy of chronic HCV remains problematic, as it causes
unpleasant side effects that could affect the patients’
HRQoL [34, 35]. Therefore, a new DAAs therapy has been
developed and has been found to be a well-tolerated ther-
apy with low adverse side effects [10, 13]. Although the
benefits of DAAs therapy are well established; its effects
on HRQoL are less certain [10, 37]. Therefore, this pro-
spective observational study is the first study to evaluate a
number of PROs, including HRQoL, mental health status
(i.e. depression, anxiety and stress), and perceived social
support among Egyptian HCV patients, while receiving
DAAs therapy; either a dual or triple therapy. Conse-
quently, this section provides an interpretation of the
study’s results based on the stated three aims, implications
for nursing practice and suggested recommendations for
future research and limitations of the study.
This study recruited 62 patients with HCV who were
treated with DAAs. Our study provides several new and
important lines of evidence about these patients’
Table 2 Comparison between males and females
Mean ± Std. Deviation t
Age
• Male 49.48 ± 12.19 -3.68**
• Female 58.34 ± 5.92
PCR-T0
• Male = 28 890248.43 ± 1049454.60 2.22*
• Female = 28 411320.44 ± 451668.92
BMI-T0
• Male 29.10 ± 3.86 -2.83**
• Female 31.99 ± 4.15
MBI-T1
• Male 28.88 ± 3.83 -2.74**
• Female 31.88 ± 4.71
HRQoL-T0
• Male 23.73 ± 15.89 -3.43**
• Female 39.06 ± 19.66
Symptom Severity-T0
• Male 18.53 ± 10.30 -3.12**
• Female 27.43 ± 12.28
Symptom Hindrance-T0
• Male 5.20 ± 6.66 -3.27**
• Female 11.62 ± 8.57
Depression-T0
• Male 5.56 ± 5.88 -3.52**
• Female 11.47 ± 7.19
Depression-T1
• Male 7.20 ± 6.46 -2.32*
• Female 11.28 ± 7.69
Note: only significant results are presented, sample of male = 30 & female = 32
PCR-T0 Polymerase Chain Reaction time0, BMI-T0 body mass index time 0, BMI-
T1 body mass index time 1, HRQoL-T0 health-related quality of life time 0
*P value: * ≤ .05, ** ≤ .001, *** ≤ .0001 at two tailed
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HRQoL, symptom experience, mental health and per-
ceived social support of patients receiving DAAs (Dual
and triple therapy) that will enhance health care pro-
viders’ insight about these patients’ needs during the
course of therapy.
Objective 1: PROs of HCV patients receiving DAAs
therapy prior, during and at the end of therapy
Our study clearly documented the effect of time on
HRQoL, symptom experience, mental health and per-
ceived social support. There was a significant effect for
time on HRQoL; it was significantly poorer after 5/
6 weeks (peak point of impairment) of therapy than at
the baseline and at the end of therapy. It is interesting
that the HRQoL score significantly increased from T0 to
T1, indicting impairment of HRQoL and then backed to
baseline score. This finding is very important as it con-
firms the need for follow up and tracking of the HRQoL
among patients on antiviral therapy. Previously, it was
ascertained that in addition to the baseline impairment
of HRQoL in patients with chronic HCV, treatment regi-
mens can impose additional PROs burdens [38]. This
impairment is further amplified by the antiviral (peg-IFN
and RBV) side effects, particularly anemia and depres-
sion. Similarly, non cirrhotic patients who received triple
Table 3 PROs of HCV patients receiving DAAs therapy prior, during and at the end of therapy
Variables/Time Friedman test Wilcoxon test
N Mean + SD Chi-Square P-value T Z P value (r)
HRQoL
T0 36 31.02 ± 15.30 8.35 .01 T0 - T1 = 436 -2.37 .01 (-.30)
T1 36 39.63 ± 21.11
T2 36 34.50 ± 19.96 T1 –T2 = 178.50 -2.04 .04(-.26)
Symptom experience
Symptom severity
T0 36 23.19 ± 10.21 5.41 .06 T0 - T1 = 458 -1.97 .04(-.25)
T1 36 27.36 ± 13.07
T2 36 24.25 ± 12.75
Symptom hindrance
T0 36 7.83 ± 6.40 9.89 .007 T0 - T1 = 358 -2.58 .01(-.33)
T1 36 12.27 ± 9.00
T2 36 10.25 ± 7.89
Mental Health
Depression
T0 36 8.91 ± 7.25 8.79 .01 T0 - T1 = 385 -2.28 .02(-.29)
T1 36 10.77 ± 7.18
T2 36 8.97 ± 6.57
Anxiety
T0 36 7.33 ± 5.80 6.82 .03 T0 - T1 = 379 -2.57 .01(-.33)
T1 36 8.88 ± 5.87
T2 36 6.86 ± 6.05 T1 - T2 = 80 -2.63 .009(-.34)
Stress
T0 36 10.94 ± 7.35 4.86 .08 T1 - T2 = 103.50 -2.47 .01(-.32)
T1 36 12.05 ± 6.83
T2 36 9.75 ± 6.80
MSPSS
T0 36 2.41 ± .47 11.35 .003 T0 - T1 = 212 -2.27 .02(-.29)
T1 36 2.51 ± .37
T2 36 2.41 ± .39 T1 - T2 = 146 -2.77 .006(-.36)
HRQoL Health-related quality of life time 0, T0 time 0, T1 time 1, T2 time 2
P value significant at two tailed
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therapy had significant impairments in HRQoL using
Short Form (SF)-36. Dual therapy was also associated with
moderate HRQoL and work productivity impairment re-
gardless of the stage of fibrosis for role physical and role
emotional of SF-36, but this impairment was significantly
lower when compared to triple therapy [10]. Younossi et
al [10]. showed that at week 4 of active treatment with
DAAs therapy (Ledipasvir and Sofosbuvir), a significant
decline in some domains of HRQoL was observed in pa-
tients without and with mild fibrosis, including physical
and social functioning, role physical and emotional, and
vitality of SF-36, physical and functional well-being and fa-
tigue, and activity/energy domain of Chronic Liver Disease
Questionnaire-HCV (CLDQ-HCV).
However, our study showed that by the end of therapy
the scores of HRQoL, mental health and symptom ex-
perience were almost back to baseline score. A previous
study on other hand showed that by the end of treat-
ment, a more substantial deterioration was observed in
most of the HRQoL domains including role physical and
role emotional of SF-36 regardless of patients’ fibrosis
status [10]. Furthermore, at the end of treatment, per-
ceived general health, emotional well-being, and worry
domains significantly improved in both fibrosis cohorts.
At follow-up, all HRQL domains and work productivity
returned to their baseline levels or moderately improved
as early as post-treatment week 4 [10].
Time also significantly impacted on symptom experi-
ence (severity & hindrance) and mental health (depres-
sion & anxiety). Symptom hindrance and mental health
were significantly poorer at T1 (5/6 weeks of therapy)
than at baseline (T0). Additionally, anxiety and stress
were significantly higher during the treatment period
(T1) than at the end of treatment (T2). Interestingly,
anxiety at baseline, after 5/6 weeks and at the end of
therapy, was significantly associated with severity and
hindrance of symptoms and HRQoL at different points
in time (p < 0.02, r ranged from 0.38 to 0.79). Previously,
it was ascertained that in addition to the baseline im-
pairment of mental health of patients with chronic HCV,
treatment regimens can impose additional mental health
impairment [25]. Therefore, it was unsurprising to find
perceived social support significantly higher during the
treatment period than at baseline (T0) and end of ther-
apy (T2). For that reason, more healthcare support is re-
quired during the course of therapy, particularly to
improve HRQoL, symptom experience and mental
health, which have been found to significantly worsen
during the course of therapy.
Comparison of basic demographic and medical data
between dual and triple users
For the purpose of comparing the dual vs. the triple
therapy users, the baseline demographic and medical
characteristics of the two groups of participants were
initially compared. We found that the dual participants
were less educated, more likely to live in urban areas
and more cirrhotic than triple users. At the time of data
collection in Egypt, two treatment regimens were deliv-
ered according to the guideline protocol of the National
Committee of Control HCV (NCCVH) for patients with
Table 4 Comparison of basic demographic and medical data
between dual and triple users
Variables Type of therapy P value Sig.
(2-tailed)Dual (n = 31) Triple (n = 31)
Gender
• Male 12 18 .20
• Female 19 13
Education
• Uneducated 17 7 .02
• Educated 14 24
Employment
• Employed 6 11 .24
•
Unemployed
8 9
• Housewives 17 11
Martial status
• Single 8 9 .50
• Married 23 22
Area of residence
• Rural 3 12 .02
• Urban 28 19
Treatment experience
• Naïve 30 24 .05
• Experience 1 7
Diagnosis
• Non-
cirrhotic
10 21 .01
• Cirrhotic 21 10
Mean ± SD
Age
56.47 ± 9.32 51.65 ± 11.03 .07
Disease duration (months)
81.71 ± 62.86 60.48 ± 50.94 .15
PCR-T0
655845.81 ±
997681.03
645348.15 ±
638028.61
.96
PCR-T1 (50 cases)
• Negative 32 (51.6%)
• Positive 18 (29.0%)
PCR-T0 Polymerase Chain Reaction time 0, PCR-T1 Polymerase Chain Reaction
time 1
P value significant at two tailed
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HCV. According to this guideline, patients with more
advanced liver disease were always ineligible for peg-IFN
treatment and thus dual therapy was presented to them.
This could help explain our findings, which also confirm
that our sample was representative of HCV patients who
received DAAs therapy at that time.
Comparison of HRQoL, mental health and symptom
experience between dual and triple users
Similar to an earlier study [36], we found that prior
to therapy HRQoL was not significantly different be-
tween dual and triple users. Also, mental health sta-
tus, symptom experience and perceived support were
similar. However the triple users were more likely to
experience more deterioration in their HRQoL and
higher levels of anxiety during the course of therapy.
These findings might be due to the fact that the ef-
fect of Peg-IFN on patients’ HRQoL and anxiety was
found to be higher than the effect of a Peg-IFN-free
regimen. However, the adherence score was high and
similar in dual and triple users, indicating the effect
of treatment on HRQoL and anxiety. It is well estab-
lished that HCV infection is associated with poorer
HRQoL and a part of impaired health of these pa-
tients is related to comorbid psychiatric disorders and
interferon treatment. Interferon treatment is an
Table 5 PROs prior, during and at the end of treatment among dual and triple users
Type of therapy Independent-samples Mann-Whitney U Test
Dual N =31 Triple N = 31 P value Sig. (2-tailed)
Baseline X ± SD
BMI-T0 31.26 ± 4.16 29.92 ± 4.26 .31
HRQoL-T0 32.54 ± 21.23 30.74 ± 17.67 .85
Symptom Severity-T0 23.32 ± 13.14 22.93 ± 11.24 .97
Symptom Hindrance-T0 9.22 ± 9.09 7.80 ± 7.50 .64
MSPSS-T0 2.22 ± .57 2.49 ± .39 .05
Depression-T0 9.12 ± 7.51 8.09 ± 6.92 .59
Anxiety-T0 6.41 ± 5.83 7.51 ± 6.03 .53
Stress-T0 8.64 ± 6.61 10.80 ± 7.63 .29
After 5/6 weeks X ± SD
BM-IT1 31.24 ± 4.47 29.60 ± 4.50 .16
HRQoL-T1 31.06 ± 24.06 41.54 ± 21.62 .04
Symptom Severity-T1 21.77 ± 15.09 28.51 ± 12.72 .05
Symptom Hindrance-T1 9.29 ± 9.64 13.03 ± 9.67 .09
MSPSS-T1 2.34 ± .55 2.54 ± .38 .23
Depression-T1 9.12 ± 7.67 9.48 ± 7.15 .72
Anxiety-T1 5.64 ± 5.77 9.19 ± 6.16 .01
Stress-T1 9.00 ± 7.46 11.87 ± 7.09 .11
INDEXSCORE-T1 15.74 ± .77 15.45 ± 1.45 .87
At the end of therapy X ± SD
HRQoL-T2 26.60 ± 17.01 37.53 ± 20.47 .15
Symptom Severity-T2 18.20 ± 12.50 26.57 ± 12.29 .06
Symptom Hindrance-T2 8.40 ± 5.10 10.96 ± 8.72 .52
MSPSS-T2 2.40 ± .40 2.41 ± .40 .84
Depression-T2 6.20 ± 6.49 10.03 ± 6.40 .10
Anxiety-T2 4.50 ± 3.53 7.76 ± 6.61 .27
Stress-T2 6.40 ± 5.16 11.03 ± 6.99 .08
INDEXSCORE-T2 15.90 ± .31 15.30 ± 1.46 .41
BMI-T0 body mass index time 0, HRQoL-T0 health-related quality of life time 0, MSPSS-T0 Multidimensional Scale of Perceived Social Support time 0, BMI-T1 body
mass index time 1, HRQoL-T1 health-related quality of life time 1, MSPSS-T1 Multidimensional Scale of Perceived Social Support time 1, INDEXSCORE-T1 The total
index score of the Center for Adherence Support Evaluation (CASE) Index time 1, HRQoL-T2 health-related quality of life time 2, MSPSS-T2 Multidimensional Scale
of Perceived Social Support time 2, INDEXSCORE-T2 The total index score of the Center for Adherence Support Evaluation (CASE) Index time 2
P value significant at two tailed
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important cause of depression and anxiety in HCV
patients and is sometimes associated with irritability,
manic episodes, or acute confusional state [39]. Inter-
feron is associated significantly with increased somatic
but not cognitive affective symptoms of depression
and with increased anxiety and fatigue during
treatment [40].
At the end of therapy, the perceived support was not
significantly different among dual and triple users. How-
ever, there was a significant effect of time on changing
the score of perceived social support, where dual and
triple users reported higher perceived support during
the course of therapy than in baseline and end of
therapy. This finding was similar to previous studies that
reported that with increasing disease severity there is in-
creased family support [29, 41].
By the end of therapy, it was observed that the mean
score of HRQoL, symptom severity and hindrance, de-
pression, anxiety and stress, had improved in the two
arms of therapy, with no significant difference between
them. On the other hand, in the only recent large identi-
fied study, fatigue, HRQoL using a disease specific
CLDQ-HCV and generic SF-36 and work productivity
were examined between patients receiving the triple
therapy and patients receiving dual therapy [25]. It was
found that patients receiving the triple therapy (n = 327)
Table 6 Pattern of change in PROs among dual and triple users prior, during and at the end of treatment
Variables/Time Triple therapy N = 26 Dual therapy N = 10
Mean + SD Chi-Square P-value Mean + SD Chi-Square P-value
HRQoL
T0 29.81 ± 15.87 10.26 .006 34.20 ± 13.98 .47 .79
T1 43.35 ± 21.15 30.00 ± 18.63
T2 37.54 ± 20.47 26.60 ± 17.02
Symptom experience
Symptom severity
T0 22.69 ± 10.29 8.00 .01 24.50 ± 10.46 .68 .71
T1 29.77 ± 12.31 21.10 ± 13.54
T2 26.58 ± 12.29 18.20 ± 12.51
Symptom hindrance
T0 7.12 ± 6.67 13.01 .001 9.70 ± 5.54 .15 .92
T1 13.58 ± 9.66 8.90 ± 6.23
T2 10.96 ± 8.72 8.40 ± 5.10
Mental Health
Depression
T0 8.58 ± 6.65 11.40 .003 9.80 ± 8.99 5.70 .05
T1 10.62 ± 6.93 11.20 ± 8.18
T2 10.04 ± 6.40 6.20 ± 6.49
Anxiety
T0 7.69 ± 6.04 4.95 .08 6.40 ± 5.29 2.10 .34
T1 9.62 ± 5.97 7.00 ± 5.46
T2 7.77 ± 6.62 4.50 ± 3.54
Stress
T0 11.54 ± 7.27 4.93 .08 9.40 ± 7.72 .70 .70
T1 12.92 ± 6.63 9.80 ± 7.19
T2 11.04 ± 6.99 6.40 ± 5.17
MSPSS
T0 2.45 ± .40 6.65 .03 2.31 ± .64 6.58 .03
T1 2.54 ± .35 2.43 ± .44
T2 2.42 ± .40 2.41 ± .41
HRQoL health-related quality of life, T0 time 0, T1time 1, T2time 2, MSPSS Multidimensional Scale of Perceived Social Support
P value significant at two tailed
Youssef et al. BMC Gastroenterology  (2017) 17:18 Page 11 of 16
experienced poorer HRQoL and work productivity than
patients receiving the dual therapy (n = 201) (p ≤ 0.01) at
the end of treatment [25]. Interferon in general has a
negative impact on patients’ HRQoL during the course
of therapy and the potential low adherence to the treat-
ment regimen was confirmed [42, 43]. Otherwise, our
study found no significant difference between the two
regimens, although the dual therapy had a minimal
negative impact on patients’ HRQoL compared to the
triple therapy. Our explanation is that the shorter dur-
ation of the treatment course (24/12 weeks according to
the regimen type) may have been related to the lower
treatment-related PROs burden of these patients and
therefore enhancing their adherence level to medication
would be expected [25]. However, it may also be due to
the difference in methodology used between our study
and Younossi’s study [25] in terms of questionnaires
used and time point measurements. Also, the sample
size was smaller than previous studies, which might not
be helpful in finding a significant difference at the end of
therapy between the two groups of therapy.
Objective 2: PROs of dual users versus triple users prior,
during and at the end of treatment
A comparison of the pattern of change in PROs among
triple and dual therapy users through the three time pe-
riods revealed that triple therapy users were significantly
more likely to report poorer HRQoL, symptom severity,
symptom hindrance and depression, and increase in
perceived social support score at T1 than at baseline. In
contrast, dual users had no significant change in their
HRQoL, symptom experience and mental health, while
their perceived social support was significantly increased
during T1 in comparing to T0 and T2 like triple therapy
users. This finding indicates that whatever the type of
therapy, patients reported a high perceived support from
their spouse, family and friends. Culturally this finding is
unsurprising as social support increases during illness.
Previously, interferon-free regimens have a modest nega-
tive effect on PROs whatever the disease stage [44].
Objective 3: Predictors of HRQoL of DAAs therapy users
prior, during and at the end of therapy
A number of multivariate analyses were run to identify
the independent predictors of HRQoL at the three dif-
ferent points in time. At baseline, the eight factors in the
model significantly explained 37.5% of the variance in
overall HRQoL prior to therapy. However, only anxiety
and depression were significant variables, which appear
to be the key determinants for HRQoL prior to therapy.
Similar to a previous study [25], our study showed that
pre-treatment depression and anxiety are the major fac-
tors associated with impaired HRQoL among patients
with HCV before initiation of treatment. The high
prevalence of depression, stress and anxiety in patients
with HCV before the initiation of treatment has previ-
ously been reported [36]. Using the backwards multivari-
ate linear regression, Bonkovsky et al [33] found that
Table 7 Predictors of HRQoL of DAAs therapy users prior, during and at the end of therapy
Model Summary of
the model
Unstandardized
Coefficients
Standardized
Coefficients
95.0% Confidence Interval
for B
Collinearity
Statistics
R R2 AdjR2 B Beta t Sig. Lower
Bound
Upper
Bound
Tolerance VIF
T0 (Constant) .63 .39 .38 15.79 4.46 .000 8.69 22.89
Depression-T0 1.11 .41 3.13 .003 .39 1.83 .65 1.53
Anxiety-T0 .98 .29 2.21 .032 .09 1.87 .65 1.53
T1 (Constant) .88 .78 .76 18.13 1.45 .153 -6.95 43.21
Stress-T1 1.39 .44 4.04 .000 .70 2.09 .36 2.76
HRQoL-T0 .37 .31 3.54 .001 .16 .58 .56 1.77
Anxiety-T1 .91 .24 2.27 .028 .10 1.72 .37 2.66
BMI-T1 -2.39 -.47 -2.82 .007 -4.11 -.69 .16 6.25
BMI-T0 1.91 .35 2.12 .040 .09 3.730 .15 6.32
T2 (Constant) .91 .83 .81 34.92 3.42 .002 13.97 55.87
HRQoL-T1 .68 .72 5.52 .000 .43 .93 .36 2.72
Anxiety-T2 2.11 .66 5.27 .000 1.29 2.93 .46 2.17
MSPSS-T2 -12.81 -.25 -3.09 .005 -21.33 -4.29 .93 1.06
Anxiety-T1 -1.14 -.33 -2.11 .044 -2.25 -.03 .25 3.91
HRQoL-T0 health-related quality of life time 0, BMI-T1 body mass index time 1, BMI-T0 body mass index time 0, HRQoL-T1 health-related quality of life time 1,
MSPSS-T2 Multidimensional Scale of Perceived Social Support time 2
P value significant at two tailed
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depression and anxiety [using the Beck Depression In-
ventory (BDI)] were significantly associated with im-
paired HRQoL summary scores (using the SF-36). It was
also reported that the severity of depressive symptoms
was highly correlated with fatigue severity, functional
disability and somatization [45]. Baseline depression,
anxiety, treatment-related adverse events and cirrhosis
have been found to be the most consistent independent
predictors of disease specific quality of life using the
CLDQ-HCV at all points in time [25, 36]. In patients
with cirrhosis who were treated with dual or triple ther-
apy, the multivariate analysis at baseline showed that,
being female, baseline depression, anxiety, insomnia, fa-
tigue, a history of unsuccessful treatment, and having
cirrhosis were associated with more impairment in PROs
(i.e. Functional Assessment of Chronic Illness Therapy-
Fatigue, CLDQ-HCV, Work Productivity and Activity
Impairment Questionnaire: Specific Health Problem
[WPAI-SHP]) scores. Furthermore, during treatment, re-
ceiving an IFN-containing regimen was another inde-
pendent predictor of PROs impairment, whereas having
cirrhosis was no longer associated with any of the PROs
impairment during treatment [44].
Accordingly, whatever the liver disease stage and the
instruments that were used to examine the association
between mental health status and HRQoL, it has been
found that depression and anxiety were significantly as-
sociated with HRQoL of patients with HCV. Therefore,
the high prevalence of depression and anxiety symptoms
among HCV patients not receiving antiviral therapy
have justified the importance of regular psychosocial
screening and support for them independent of antiviral
therapy [45]. It is important to keep in mind that, prior
to the initiation of treatment, patients with HCV ap-
peared to experience impairment of their HRQoL [38].
In a cross-sectional study of 81 HCV-infected patients
who were not receiving antiviral therapy, anxiety, de-
pression, psychopathological symptoms, social support
and resilience were assessed [41]. It was found that de-
pression and anxiety scores were significantly higher
among HCV patients than in a healthy control group
[41] as 62.9% of HCV patients had a major depressive
disorder diagnosis, and 42.3% had significant depressive
symptoms, according to the BDI-II [46].
After 5 to 6 weeks of therapy (T1), the model signifi-
cantly explained 76% of the variance in the HRQoL.
HRQoL T0 & BMI T0 prior to therapy; and Stress T1,
Anxiety T1 & BMI T1 during therapy significantly ex-
plained the variation in HRQoL during the course of
therapy. These findings give support to the important
role that these factors play in HRQoL of HCV patients
during therapy. These results were previously unknown;
therefore, it was difficult to compare our study’s findings
with previous studies. In patients with cirrhosis who
were treated with dual or triple therapy, the multivariate
analysis during treatment (4 weeks after starting therapy)
showed that being female, baseline depression, anxiety,
insomnia, fatigue, and having a history of unsuccessful
treatment, and receiving an IFN-containing regimen
were the predictors of PROs impairment [Functional As-
sessment of Chronic Illness Therapy-Fatigue, CLDQ-
HCV, WPAI-SHP]), whereas having cirrhosis was not
associated with any of the PROs impairment during
treatment [44].
Based on our study’s findings, we recommend that
baseline HRQoL and BMI should be systematically
assessed before starting the antiviral therapy for early de-
tection and the improvement of the impairment before
the initiation of therapy. Also, the patients’ anxiety,
stress and BMI should be frequently assessed and
followed up through the course of antiviral therapy.
Additionally, HRQoL & anxiety during the course of
therapy and perceived support & anxiety at the end of
therapy significantly and respectively predict the varia-
tions in HRQoL T2 at the end of therapy. A pervious
study found that a history of pre-treatment anxiety, de-
pression, fatigue, female gender, and presence of cirrho-
sis were major predictors of disease specific quality of
life impairment [25].
Additionally, our results confirmed previously reported
data that anxiety is one of the major constant predictors
of HRQoL impairment (at different time points) [25].
Therefore, health care providers should develop a sup-
portive care program to help decrease anxiety levels that
might later impact on these patients HRQoL. Studying
this relationship in these patients is highly recom-
mended. Also, a comprehensive care plan including all
these associated factors is urgently needed to avoid the
deterioration of patients’ HRQoL during the course of
therapy. Also, an exploration of the causes of increased
anxiety among HCV patients at baseline and during the
course of antiviral therapy is required.
Comparison between males and females
We found that females had a higher depression level and
an increased impaired HRQoL than males prior to treat-
ment even after controlling for age, PCR T0, BMI T0
and duration of disease in months. A comparison be-
tween male and female patients revealed that our find-
ings were similar to a previous study [36]. Bonkovsky et
al. [33], using a multivariate model, found that female
gender, greater BMI, older age, current cigarette smok-
ing, a higher depression score, and use of antidepressant
or anxiolytic medications at baseline were significant
predictors of poor HRQoL, particularly of the physical
summary score among HCV patients [33]. However, at
the end of treatment, our study did not agree with the
findings of a previous study [36] which found that
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females had poorer PRQs than males at the end of
treatment.
Interestingly, although females had a significantly
lower PCR (viral load) than males prior to therapy, they
experienced poorer HRQoL, higher depression, higher
symptom severity and hindrance of symptoms. Similarly,
Younossi et al (2014) [36] found that females, without
considering the viral load, showed more impairment in
PROs than males; including physical components of SF-
36, physical well-being, fatigue, systematic domains of
CLDQ-HCV and activity impairment. Clearly, further re-
search is required to investigate this further.
Nurses and healthcare providers should therefore care
for these female patients, particularly their mental health
status and depression symptoms, by developing inter-
vention programs that aim to improve their mental
health status, which will be reflected on their HRQoL
and their overall life. Due to the reduced sample size at
time points two and three (T1 & T2), there is an urgent
need to repeat this study, but using a larger balanced
sample of male and female patients in Egypt and
elsewhere.
Recommendations
Anxiety has been found to be high in patients receiving
HCV antiviral therapy, particularly those following triple
therapy. Consequently, we highly recommend that anx-
iety among these patients be systematically researched
and analysed and a nursing intervention plan be devel-
oped to support these individuals. The patient’s perspec-
tive in terms of PROs (i.e. HRQoL, mental health and
perceived social support) must be considered by nurses
and healthcare providers regularly in the plan of care to
improve treatment experience by decreasing the treat-
ment burden.
A symptom management program should be devel-
oped and delivered by highly qualified and well trained
nurses to HCV-patients who attend regular consulta-
tions during the antiviral therapy. Also, a phone number
should be available for delivering symptom management
advice at any time and at any place according to the pa-
tient’s needs and without interrupting the health care
providers’ work. Designing simple illustrated educational
materials as guidance would be helpful to answer some
of these patients’ questions and explain the treatments
adverse effects as well as how to overcome them during
the course of therapy.
Although this study used a quantitative approach,
some patients gave qualitative comments to “explain”
their answer, which increased the understanding of pa-
tients’ suffering as well as their needs. Therefore, a quali-
tative approach is recommended to explore psychosocial
needs and to suggest self-care approaches that can help
these patients to overcome the medications adverse ef-
fects as well as symptom hindrance.
Face to face interviews were used to complete the in-
struments, as most of the patients were uneducated.
This approach was time consuming to the researcher as
well as to the participants. Thus, it was appropriate to
use only a disease specific HRQoL questionnaire (i.e.
LDSI-2.0) alongside the other instruments. Using a dis-
ease specific HRQoL questionnaire was helpful in identi-
fying the unique symptoms experienced by patients on
antiviral therapy. Subsequently, we recommend that fu-
ture studies demonstrate both generic and disease spe-
cific HRQoL measurements to gain more insights into
patterns of change in various domains of HRQoL among
these patients, and which domains are more likely to be
affected during the course of therapy.
Health-related quality of life is a complex concept with
numerous dimensions. It should be an important out-
come measure for all persons with HCV generally, and
on antiviral therapy specifically, to ensure that the
healthcare resources and medical treatment, as well as
nursing interventions offered to this population are pro-
viding an improvement in patient’s daily activities and
well-being. Ascertaining HRQoL requires engaging the
patients in their plan of treatment and intervention, as
this cannot be ascertained independently by a clinician
or the nurse.
Potential limitations
The fact that patients know whether they have
responded to treatment when they complete the
HRQOL instruments, has been considered a potential
confounder in most longitudinal studies of HRQOL in
chronic hepatitis C [33]. However, in this study we could
not control patients’ and health care providers’ blindness
to the PCR results at the time of data collection. There-
fore, some of the patients did know their PCR results
during data collection, which may have affected the pa-
tients’ anxiety level as well as their HRQoL.
The participants were recruited from one centre
largely due to the resources available to the research
team. It was felt however, that a representative sample
was obtained, as all the other centres were very similar
in patient demographics, as well as clinic resources, pol-
icies and procedures. All these centres follow the same
set of national guidelines for the treatment of patients
with chronic HCV and are supervised by the NCCVH.
The limited sample size may have been one of the rea-
sons that we found no significant association between
some of the studied variables. Replicating this study with
a larger sample of patients is needed to establish the reli-
ability of these results.
Taking into consideration the real life nature of the
treatment, losses in the availability of laboratory results
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during treatment and follow up did occur, which made it
difficult to keep data consistency. Therefore, a future
study should consider the haemoglobin levels during the
follow up of the HRQoL.
Conclusions
This study found a significant change in HRQoL across
the three different time periods among patients receiving
DAAs. Only perceived support at baseline and anxiety
during treatment were significantly higher among the
triple therapy group than dual group when comparing
the three different time points. At baseline, depression
was the main variable that contributed to predicting
change in HRQoL prior to therapy. During therapy,
stress-T1, body mass index (BMI)-T1 and HRQoL-T0
significantly and respectively predicted HRQoL-T1. At
the end of therapy, HRQoL-T1 and anxiety-T2 signifi-
cantly predicted the variation in HRQoL-T2.
This study’s findings highlight the critical importance
of assessing HRQoL, mental health and perceived social
support in patients receiving HCV antiviral therapy.
These study’s findings add value to what is important to
healthcare providers by including outcomes from the pa-
tients’ perspective. Therefore, the patient’s perspective in
terms of HRQoL, mental health and perceived social
support should be fully considered by nurses and health-
care providers when planning care.
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